XHKG
0897
Market cap50mUSD
Jun 06, Last price
0.35HKD
1D
0.00%
1Q
0.00%
Jan 2017
-7.89%
Name
Wai Yuen Tong Medicine Holdings Ltd
Chart & Performance
Profile
Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicines, Western pharmaceutical products, and health food and personal products in Hong Kong, Mainland China, Macau, and internationally. The company offers Chinese medicines and health food products under the Wai Yuen Tong brand name; and Western pharmaceutical and personal care products under the Madame Pearl's and Pearl's brands. It also engages in the investment, holding, and selling of properties; provision of financial services; and agricultural produce exchange market operation. As of March 31, 2022, the company operated 63 retail stores in Hong Kong. The company was founded in 1897 and is headquartered in Kowloon Bay, Hong Kong. Wai Yuen Tong Medicine Holdings Limited is a subsidiary of Rich Time Strategy Limited.
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
Income | |||||||||
Revenues | 783,881 -39.07% | 1,286,428 -7.55% | |||||||
Cost of revenue | 745,832 | 1,200,276 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 38,049 | 86,152 | |||||||
NOPBT Margin | 4.85% | 6.70% | |||||||
Operating Taxes | (6,359) | (15,283) | |||||||
Tax Rate | |||||||||
NOPAT | 44,408 | 101,435 | |||||||
Net income | (15,356) -25.15% | (20,515) -81.16% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (14,728) | (9,960) | |||||||
BB yield | 5.11% | 2.27% | |||||||
Debt | |||||||||
Debt current | 283,869 | 666,552 | |||||||
Long-term debt | 375,320 | 1,098,066 | |||||||
Deferred revenue | 65,605 | ||||||||
Other long-term liabilities | 51,220 | 798 | |||||||
Net debt | (104,908) | (2,181,971) | |||||||
Cash flow | |||||||||
Cash from operating activities | 191,688 | 91,578 | |||||||
CAPEX | (34,649) | (33,446) | |||||||
Cash from investing activities | (84,621) | 15,065 | |||||||
Cash from financing activities | (469,969) | (67,250) | |||||||
FCF | 877,628 | 7,470 | |||||||
Balance | |||||||||
Cash | 196,781 | 625,006 | |||||||
Long term investments | 567,316 | 3,321,583 | |||||||
Excess cash | 724,903 | 3,882,268 | |||||||
Stockholders' equity | (42,404) | 1,315,582 | |||||||
Invested Capital | 2,039,149 | 4,042,370 | |||||||
ROIC | 1.46% | 2.51% | |||||||
ROCE | 1.90% | 1.45% | |||||||
EV | |||||||||
Common stock shares outstanding | 1,181,346 | 1,216,213 | |||||||
Price | 0.24 -32.22% | 0.36 24.14% | |||||||
Market cap | 288,248 -34.17% | 437,837 22.58% | |||||||
EV | 212,480 | (404,941) | |||||||
EBITDA | 149,199 | 199,201 | |||||||
EV/EBITDA | 1.42 | ||||||||
Interest | 40,792 | 106,306 | |||||||
Interest/NOPBT | 107.21% | 123.39% |